Tackling osimertinib resistance in EGFR mutant non-small cell lung cancer

Autores organización

• 

  Andres Felipe Cardona Mendoza

  Autor

Autores

• Blaquier JB
• Ortiz-Cuaran S
• Ricciuti B
• Mezquita L
• Recondo G

Grupos de investigación

• Grupo de Inmunología celular y molecular Universidad El Bosque (InmuBo)

  Investigador

  Maria Consuelo Romero Sanchez

Resumen

The current landscape of targeted therapies directed against oncogenic driver alterations in non-small cell lung cancer (NSCLC) is expanding. Patients with EGFR mutant NSCLC can derive significant benefit from EGFR tyrosine kinase inhibitor (TKI) therapy, including the third-generation EGFR TKI osimertinib. However, invariably, all patients will experience disease progression with this therapy mainly due to the adaptation of cancer cells through primary or secondary molecular mechanisms of resistance. The comprehension and access to tissue and cell-free DNA next-generation sequencing has fueled the development of innovative therapeutic strategies to prevent and overcome resistance to osimertinib in the clinical setting. Herein, we review the biological and clinical implications of molecular mechanisms of osimertinib resistance and the ongoing development of therapeutic strategies to overcome or prevent resistance. © 2023 American Association for Cancer Research Inc.. All rights reserved.

©2023 American Association for Cancer Research.

Keywords

• Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; abemaciclib; afatinib; alectinib; alisertib; amivantamab; antineoplastic agent; apg 1252; atezolizumab; bbt 176; bevacizumab; blu 525; blu 701; blu 945; bufalin; carotuximab; cell free DNA; cetuximab; cisplatin; dabrafenib; datopotamab deruxtecan; DNA; docetaxel; eai 001; epidermal growth factor receptor; epidermal growth factor receptor kinase inhibitor; erlotinib; gefitinib; honokiol; immune checkpoint inhibitor; jbj 04 125 02; jin a 02; lazertinib; minnelide; mrk 2843; n [3 [[5 chloro 2 [[2 methoxy 4 (4 methyl 1 piperazinyl)phenyl]amino] 4 pyrimidinyl]oxy]phenyl]acrylamide; navitoclax; necitumumab; niraparib; nivolumab; obx 02 011; osimertinib; patritumab deruxtecan; pembrolizumab; pemetrexed; platinum complex; programmed death 1 ligand 1 inhibitor; quaratusugene ozeplasmid; repotrectinib; savolitinib; selpercatinib; selumetinib;